| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.065 | 0.04 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.098 | 0.04 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.04 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.04 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.04 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.04 |